A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.
In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardised rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.
Excision of a primary tumour remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.
“The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole”, says Professor Renaldas Raišutis, head of the team behind the research at Kaunas University of Technology.
In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analysing complex data on skin tumours recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.
“An efficient diagnosis of an early-stage malignant skin tumour could save critical time: more patients could be examined and more of them could be saved”, says Prof Raišutis.
According to Prof Raišutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.
Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.
The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Researchers and patients in North Wales to support national multi-cancer detection test trial
Betsi Cadwaladr University Health Board staff and patients across North Wales are supporting a new trial to help evaluate a new multi-cancer detection test. The Health Board has joined Health and Care ...
- The Healthcare community encourages yearly cancer screenings amidst the pandemic
Preventative healthcare has been put on hold during the pandemic and health officials naitonally and locally say annual cancer screenings have decreased drastically ...
- 'Early detection is key' | York County Arts Council offers Mobile 3D Mammogram Screenings
Early detection can be key to preventing diseases or cancers from affecting one's quality of life. The Arts Council of York County is planning a mammography event in Old Town Rock Hill next month to ...
- New artificial intelligence tool may ‘save lives’ detecting prostate cancer, FDA says
Artificial intelligence is playing a crucial role in detecting prostate cancer, according to t. The federal agency approved the use of Paige Pr ...
- Report: Latinos have higher rates of preventable cancer
Data: Miller et al., Cancer statistics for the US Hispanic/Latino population, 2021; Chart: Will Chase/AxiosU.S. Latinos are more likely to suffer from potentially preventable cancers than non-Hispanic ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Penn Medicine and Wistar Institute receive $11.7 million grant to treat melanoma
The Specialized Programs of Research Excellence, also known as SPOREs, is a five-year award to fund three new melanoma research projects.
- Cedars-Sinai Researchers Develop New Melanoma Staging System
Cedars-Sinai Cancer researchers have created a new system for classifying melanoma when the disease has spread to the lymph nodes.
- Alrizomadlin Granted FDA Fast Track Designation for Relapsed/Refractory Unresectable or Metastatic Melanoma
Patients with relapsed/refractory unresectable or metastatic melanoma may derive benefit from alrizomadlin, which has received a fast track designation from the FDA.
- Miles Against Melanoma 5K features concert
There’s far more to Saturday’s charitable 5K than just running.The Miles Against Melanoma 5K Run and 1 Mile Walk Family Fun Event has local food vendors, free beer and a concert to close out the ...
- Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects
Penn Medicine and The Wistar Institute have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.